Generic competition is dragging down revenue this year, but it has FDA approvals in the wings.
News & Analysis: Alkermes
ALKS earnings call for the period ending March 31, 2019.
Sales of the drugmaker's schizophrenia drug Aristada disappointed investors.
It took a few drugs to get there.
ALKS earnings call for the period ending December 31, 2018.
Earnings per share will more than double for each of these specialty drugmakers.
The company's ALKS-5461 failed to win over the FDA's advisory committee this month.
Upbeat quarterly results enable management to boost guidance for the full year.
ALKS earnings call for the period ending September 30, 2018.
The commercial-stage biopharma posts revenue growth of 39% thanks to increased product sales and a sizeable milestone payment.